作者: A. Ravaggi , C. Romani , B. Pasinetti , R. A. Tassi , E. Bignotti
DOI: 10.1007/S00705-006-0787-Y
关键词: Virology 、 Immune system 、 Carcinoma 、 Cervical cancer 、 Medical microbiology 、 Biology 、 Vaccination 、 Serology 、 Virus 、 Antibody
摘要: Human papillomaviruses (HPVs), particularly HPV-16/18, are linked to cervical cancer development. Full-length, recombinant HPV-16/18 E7 oncoproteins were used in a new streptavidin-biotin capture ELISA method investigate anti-HPV antibody prevalence serum. Sera from 99 healthy women, 70 patients, and 30 patients with pre-invasive neoplasia analyzed. Anti-HPV-16/18 positivity was found 53% of 40% neoplasia, 8% women. Serum samples 12 obtained at different time intervals during the treatment. Eleven out showed correspondence between HPV-E7 levels (decreasing versus increasing) type response (clinically complete or partial progression stable disease) each serological evaluation. Five recurrent HPV-16/18-positive carcinoma analyzed before after vaccination E7-pulsed autologous dendritic cells; anti-HPV-16/18 3 5 In conclusion, this assay could potentially be as an adjunctive tool monitor treatment possibly detect induction vaccination, potential marker evaluate its efficacy.